Novo Nordisk A/S 2007 AR2
The report details Novo Nordisk's financial, social, and environmental performance for the fiscal year 2007. Key highlights include a 13% sales growth in local currencies, driven by the strong performance of modern insulins, and the successful completion of phase 3 clinical trials for liraglutide. On the environmental front, the company entered a pioneering wind power partnership with DONG Energy to reduce CO2 emissions and progress toward its WWF Climate Savers target. Socially, Novo Nordisk expanded its global workforce to 26,008 employees, with the majority now based outside Denmark, and actively supported the first UN-observed World Diabetes Day.
Company: Novo Nordisk A/S
Sector: Manufacturing
Country: Denmark
Year: 2007
Type: AR2
Pages: 124
Back to company
Novo Nordisk A/S
Annual Report
The report details Novo Nordisk's financial, social, and environmental performance for the fiscal year 2007. Key highlights include a 13% sales growth in local currencies, driven by the strong performance of modern insulins, and the successful completion of phase 3 clinical trials for liraglutide. On the environmental front, the company entered a pioneering wind power partnership with DONG Energy to reduce CO2 emissions and progress toward its WWF Climate Savers target. Socially, Novo Nordisk expanded its global workforce to 26,008 employees, with the majority now based outside Denmark, and actively supported the first UN-observed World Diabetes Day.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2007
Reporting Period
Jan 1, 2007 - Dec 31, 2007
Fiscal Year
2007
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees